Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.
2.

Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.

Pian KL, Westenberg HG, van Megen HJ, den Boer JA.

Psychopharmacology (Berl). 1998 Dec;140(3):365-70.

PMID:
9877016
3.

Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.

Koran LM, Pallanti S, Quercioli L.

Eur Neuropsychopharmacol. 2001 Apr;11(2):169-72.

PMID:
11313163
4.

Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?

Whale R, Bhagwagar Z, Cowen PJ.

Psychopharmacology (Berl). 1999 Jul;145(2):223-6.

PMID:
10463324
5.

Serotonin-1D hypothesis of obsessive-compulsive disorder: an update.

Zohar J, Kennedy JL, Hollander E, Koran LM.

J Clin Psychiatry. 2004;65 Suppl 14:18-21. Review.

6.

Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).

Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S.

Br J Pharmacol. 1997 May;121(2):157-64.

7.
8.

Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques.

Vanmolkot FH, de Hoon JN, Barrington P, Peck RW, Dallow NS, Williams PM, McColm J.

Eur J Clin Pharmacol. 2002 Aug;58(5):303-8. Epub 2002 Jul 5.

PMID:
12185552
9.

Review of zolmitriptan and its clinical applications in migraine.

Dowson AJ, Charlesworth B.

Expert Opin Pharmacother. 2002 Jul;3(7):993-1005. Review.

PMID:
12083998
10.

Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.

de Almeida RM, Nikulina EM, Faccidomo S, Fish EW, Miczek KA.

Psychopharmacology (Berl). 2001 Sep;157(2):131-41.

PMID:
11594437
11.
12.

Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls.

Ho Pian KL, Westenberg HG, den Boer JA, de Bruin WI, van Rijk PP.

Biol Psychiatry. 1998 Sep 1;44(5):367-70.

PMID:
9755360
13.

Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.

MacLennan SJ, Cambridge D, Whiting MV, Marston C, Martin GR.

Eur J Pharmacol. 1998 Nov 20;361(2-3):191-7.

PMID:
9865508
14.

Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results.

Külz AK, Meinzer S, Kopasz M, Voderholzer U.

Neuropsychobiology. 2007;56(2-3):127-31. doi: 10.1159/000115778. Epub 2008 Feb 7.

PMID:
18259085
15.

The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.

Cumberbatch MJ, Hill RG, Hargreaves RJ.

Eur J Pharmacol. 1998 Nov 27;362(1):43-6.

PMID:
9865528
16.

Decreased sensitivity of 5-HT(1D) receptors in melancholic depression.

Whale R, Clifford EM, Bhagwagar Z, Cowen PJ.

Br J Psychiatry. 2001 May;178:454-7.

17.

Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.

Johnson DE, Rollema H, Schmidt AW, McHarg AD.

Eur J Pharmacol. 2001 Aug 17;425(3):203-10.

PMID:
11513839
18.
19.

Bovine isolated middle cerebral artery contractions to antimigraine drugs.

Roon KI, Maassen Van Den Brink A, Ferrari MD, Saxena PR.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):591-6.

PMID:
10598799
20.

Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.

Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J.

Neuropsychobiology. 2004;50(3):200-5.

PMID:
15365215

Supplemental Content

Support Center